Introduction

Japan's regulatory framework for wellness products is thorough, deliberate, and unforgiving of shortcuts. International brands that underestimate it burn months of effort and significant capital on preventable mistakes. Brands that respect it gain access to one of the world's highest-spending consumer markets -- and a regulatory moat that keeps less disciplined competitors out.

This guide breaks down Japan's wellness product regulations by category: supplements and health foods, cosmetics and quasi-drugs, health tech devices, and functional foods. For each category, you will find the governing laws, approval pathways, realistic timelines, and the pitfalls that trip up most first-time entrants.

⚖️ Legal Notice

This guide provides a general overview of Japan's regulatory landscape as of early 2026. Regulations change frequently. Specific requirements vary by product category, ingredient composition, and intended use. Always consult a qualified regulatory specialist or legal counsel familiar with Japanese law before making compliance decisions. This guide does not constitute legal advice.

Why Japan's Regulatory Landscape Matters

Japan's regulatory rigor is not a bureaucratic inconvenience. It is a structural feature of the market -- and a strategic advantage for brands that clear the bar.

The barrier is the moat. Once a product is properly classified, approved, and labeled for the Japanese market, competitors face the same 6-to-18-month gauntlet you went through. Speed-to-market advantages in less regulated markets do not apply here. Patience and precision are rewarded.

Consumer trust is built on regulation. Japanese consumers expect products sold in their market to have cleared a stringent review process. The FOSHU seal, for example, is one of the most recognized health certification marks among Japanese shoppers. Regulatory compliance is not just legal protection -- it is a marketing asset.

Key institutions you will encounter:

MHLW (Ministry of Health, Labour and Welfare): Sets policy and standards for pharmaceuticals, food safety, and cosmetics
PMDA (Pharmaceuticals and Medical Devices Agency): Conducts scientific reviews and pre-market evaluations
Consumer Affairs Agency (CAA): Oversees food labeling, functional claims, and advertising standards
Ministry of Economy, Trade and Industry (METI): Governs certain product safety standards

Japan's regulatory system operates on a classification-first principle. Before you consider timelines, costs, or documentation, you must determine exactly how your product is classified under Japanese law. Misclassification is the single most expensive mistake a brand can make -- it can invalidate months of preparation and force you to restart from zero.

Product Categories and Their Regulatory Paths

Supplements and Health Foods

Supplements in Japan are not regulated as drugs. They fall under the broader category of "health foods" (kenkoshokuhin) and are governed primarily by the Food Sanitation Act and the Health Promotion Act.

There are three distinct subcategories, each with a different level of regulatory burden and marketing flexibility.

FOSHU (Foods for Specified Health Uses / tokuho)

The most rigorous classification for health foods. FOSHU products carry a government-approved seal and can make specific health claims on packaging.

Requires clinical trials demonstrating safety and efficacy for the claimed health function
Approval granted by the MHLW after review by the Food Safety Commission and the Consumer Affairs Agency
As of 2024, over 1,000 products have received FOSHU certification across 13 claim categories including gut conditioning, blood pressure regulation, and fat absorption suppression (Source: Statista / CAA, 2024)
Timeline: 2 to 5 years from application to approval. This is not a typo -- the process is genuinely long
Cost: Clinical trials alone can run from $200,000 to over $1 million depending on the claim and ingredient novelty
Best for: Established brands with significant R&D budgets and a long-term Japan commitment

Foods with Function Claims (FFC / kinosei hyoji shokuhin)

A faster alternative to FOSHU, introduced in 2015. FFC products can make function claims based on scientific evidence without requiring government approval -- only notification to the CAA.

Requires a systematic literature review (now following PRISMA 2020 guidelines as of April 2025) or original clinical data (Source: ChemLinked, 2025)
Pre-market notification period: 60 days for standard ingredients, extended to 120 days for novel ingredients as of April 2025 (Source: CAA Proposal No. 235080079, 2025)
Products must include a disclaimer stating they are not intended for prevention or treatment of disease
New labeling requirements effective September 1, 2026: FFC products must display warnings about overdose risks and pharmaceutical interactions (Source: NutraIngredients, 2024)
GMP compliance mandatory from September 1, 2026 with a two-year transition period
Timeline: 3 to 6 months (including documentation preparation and the notification period)
Cost: $50,000 to $200,000 depending on whether you use existing literature or conduct original studies
Best for: Brands seeking a balance between credible health claims and manageable timeline

General Health Foods (ippan kenkoshokuhin)

The lowest regulatory burden, but with significant marketing limitations.

No specific health claims permitted on packaging or in advertising
Must comply with general food safety standards and import notification requirements
All imported food products require import notification to the MHLW quarantine station
Timeline: 1 to 3 months for import clearance
Cost: $10,000 to $30,000 for testing, labeling, and customs clearance
Best for: Brands testing the market before investing in FFC or FOSHU certification

The line between a permitted "nutritional" statement and a prohibited "health claim" is narrow in Japan. Saying "contains 500mg of Vitamin C" is fine. Saying "supports immune health" on a general health food is a regulatory violation. When in doubt, classify up -- the penalties for unauthorized claims include product seizure and market withdrawal.

Cosmetics and Quasi-Drugs

Cosmetics in Japan are governed by the Pharmaceutical and Medical Devices Act (PMD Act), overseen by MHLW and PMDA.

The critical distinction is between cosmetics (keshouhin) and quasi-drugs (iyaku-bugaihin). The classification depends on the claims you intend to make, not just the ingredients.

Cosmetics (keshouhin)

Products intended for beautifying, cleaning, or maintaining the appearance of the body through mild, non-pharmacological action.

No pre-market approval required, but products must comply with ingredient standards
Japan uses a negative list (prohibited/restricted substances) and a positive list (approved UV filters and preservatives)
A Cosmetic Manufacturing and Marketing License is required. Foreign brands typically work with a licensed Japanese partner (Source: Artixio / PMDA, 2025)
Full ingredient list in descending order of concentration, following INCI naming conventions translated to Japanese standard names
Timeline: 2 to 4 months for product registration and labeling compliance
Cost: $15,000 to $50,000 depending on the number of SKUs and ingredient complexity

Quasi-Drugs (iyaku-bugaihin)

Products making specific efficacy claims -- such as anti-dandruff, skin whitening, acne prevention, or UV protection beyond cosmetic levels -- fall into this higher category.

Pre-market approval required from MHLW
Foreign manufacturers must obtain Accredited Foreign Manufacturer status from MHLW
Active ingredients must be approved for the specific claimed function
Imported quasi-drugs require storage at customs for testing; the importer or their designated storage company must hold a manufacturing license for packaging, labeling, and storage (Source: REACH24H, 2025)
Timeline: 6 to 12 months for approval. Complex formulations may extend to 18 months
Cost: $100,000 to $500,000+ including safety and efficacy studies, accreditation, and documentation

A product that is a "cosmetic" in the U.S. or EU may be a "quasi-drug" in Japan if it makes any functional claim. Sunscreens above SPF 50, medicated shampoos, and products claiming to reduce wrinkles all fall into quasi-drug territory. Mapping your existing product claims to Japanese categories is the essential first step.

Health Tech Devices

Health tech products -- from wearable fitness trackers to red light therapy panels to cold plunge controllers -- are regulated under the PMD Act if they make any medical or therapeutic claim.

Japan classifies medical devices into four risk-based classes:

Class I (extremely low risk): General medical devices. Examples: bandages, tongue depressors, basic wellness monitors with no diagnostic claims
Class II (low risk): Controlled medical devices. Examples: blood pressure monitors, powered muscle stimulators, certain diagnostic software
Class III (medium risk): Specifically controlled devices. Examples: dialysis equipment, implantable devices, advanced diagnostic AI
Class IV (high risk): Highest-risk devices. Examples: pacemakers, stents, certain in-vitro diagnostics

Key requirements:

A Marketing Authorization Holder (MAH) license is required to sell any classified medical device in Japan
Class I devices require only notification to PMDA
Class II devices require third-party certification or PMDA approval
Class III and IV devices require direct PMDA pre-market approval with clinical data
As of February 2026, all medical devices manufactured and marketed in Japan must comply with the JIS T 0601-1-2:2023 standard (Source: Pacific Bridge Medical, 2025)
The 2025 PMD Act amendments introduced requirements for comprehensive adverse event collection systems and supply chain resilience reporting (Source: Pacific Bridge Medical, 2025)

Timeline by class:

Class I: 1 to 3 months
Class II: 6 to 12 months
Class III-IV: 12 to 24+ months

Cost range:

Class I: $20,000 to $50,000
Class II: $100,000 to $300,000
Class III-IV: $500,000 to $2 million+

The wellness gray zone. Many "wellness" devices (red light panels, percussion massagers, infrared saunas) exist in a regulatory gray zone. If the manufacturer makes no medical or therapeutic claims, the product may not fall under PMD Act jurisdiction. But the moment marketing materials reference "pain relief," "recovery acceleration," or "circulation improvement," the product enters medical device territory. Japanese regulators examine marketing materials closely -- including social media posts and influencer content.

Functional Foods and Beverages

Functional foods and beverages follow the same FOSHU/FFC/general food framework described in the supplements section above, with additional considerations:

Beverage-specific testing: Shelf-life stability, microbiological safety, and caloric content testing may be required in addition to functional ingredient verification
Novel food ingredients: Any ingredient not recognized in Japan's existing food additive lists requires a separate safety assessment before it can be used. This process adds 6 to 12 months (Source: ChemLinked, 2025)
Import notification: All food and beverage products require notification to the MHLW quarantine station at the port of entry. Products may be subject to random inspection or mandatory testing
Organic claims: The JAS (Japanese Agricultural Standards) organic certification is required to use the word "organic" (yuki) on packaging in Japan. Foreign organic certifications (USDA, EU Organic) are not automatically recognized

Regulatory compliance is where most brands stall. We handle the entire process -- from product classification to market approval, labeling review, and import logistics. Get a free regulatory assessment

Labeling Requirements

Every product sold in Japan must carry Japanese-language labeling. This is non-negotiable -- there is no grace period, no English-only option, and no exemption for e-commerce sales.

Universal requirements across all product categories:

Full ingredient list in Japanese: Following INCI conventions translated to Japanese standard names, listed in descending order of concentration
Manufacturer or importer name and address: Full legal entity name, physical address in Japan, and contact information -- in Japanese
Product name and category: Must match the regulatory classification exactly
Net content: In metric units
Country of origin: Clearly displayed
Lot number and expiry date: Required for cosmetics, food products, and quasi-drugs
Allergen declarations: Japan mandates disclosure of 8 specific allergens (including shrimp, crab, wheat, buckwheat, egg, milk, peanut, and tree nuts) with an additional 20 recommended allergens for food products
Warnings and precautions: Product-specific safety information in Japanese

Category-specific labeling:

Cosmetics: Full INCI ingredient list. UV protection products must display SPF and PA ratings per Japan's standardized measurement protocols
Quasi-drugs: Active ingredient and claimed efficacy must appear on the label. Approval number must be printed on packaging
FFC products: Function claim, disclaimer about not being a substitute for medical treatment, and notification number
Medical devices: Classification, intended use, MAH information, and any applicable warnings per PMDA guidelines

Common labeling failures:

Translation errors in ingredient names (Japanese INCI names differ from English INCI in some cases)
Missing allergen declarations
Font size below the legal minimum (8-point minimum for mandatory information)
Using claim language that exceeds what is approved for the product's classification

Timeline and Costs: From Classification to Market

The path from "we want to sell in Japan" to "products on shelves" follows a predictable sequence. Here is a realistic breakdown.

Total timeline estimates by category:

Category	Best Case	Typical	Complex/Novel
General health food	2 months	3-4 months	6 months
FFC supplement	4 months	6-8 months	12 months
FOSHU	2 years	3-4 years	5+ years
Cosmetic	2 months	3-5 months	6 months
Quasi-drug	8 months	12-15 months	18+ months
Class I device	2 months	3-4 months	6 months
Class II device	8 months	12-14 months	18 months
Class III-IV device	14 months	18-24 months	30+ months

Common Mistakes (And How to Avoid Them)

Translating Claims Directly from English

Your FDA-compliant claim language is not Japan-compliant. "Supports immune health" is a perfectly normal supplement claim in the United States. In Japan, that same phrase on a general health food triggers a regulatory violation. Each product category has a precise scope of permitted claims, and the language must be reviewed by a Japanese regulatory specialist -- not simply translated by a bilingual copywriter.

The fix: Map every claim on your existing packaging, website, and marketing materials to Japanese regulatory categories. Determine which claims you can make under your product's classification, and rewrite the rest. This is a regulatory exercise, not a translation exercise.

Underestimating the Quasi-Drug Threshold

Many brands that sell "cosmetics" globally discover that their products are "quasi-drugs" in Japan. The trigger is not the ingredients -- it is the claims. A moisturizer is a cosmetic. A moisturizer that claims to "reduce fine lines" is a quasi-drug. A shampoo is a cosmetic. A shampoo that claims to "prevent hair loss" is a quasi-drug.

The fix: Audit your product claims before you begin the regulatory process, not after. If any product makes a functional or therapeutic claim, plan for quasi-drug timelines and costs from the start.

Skipping the Japanese Labeling Review

Labeling errors are the most common cause of customs delays and product holds. Machine-translated ingredient lists, incorrect allergen declarations, and font sizes below the legal minimum are all grounds for rejection at the port.

The fix: Engage a regulatory labeling specialist who has reviewed labels for your specific product category. Have the final label reviewed by at least two native Japanese speakers -- one for regulatory accuracy, one for consumer readability.

Treating Regulatory Compliance as a One-Time Event

Japan's regulatory environment evolves continuously. The FFC notification period was extended from 60 to 120 days for novel ingredients in April 2025. New GMP requirements take effect in September 2026. The PMD Act was amended in May 2025 with new adverse event reporting obligations. A product that was compliant when you launched may fall out of compliance as regulations update.

The fix: Establish a regulatory monitoring process. Subscribe to PMDA and CAA regulatory update notifications. Budget for annual compliance reviews, especially in the first three years after market entry.

Frequently Asked Questions

Ready to Navigate Japan's Regulations?

Japan's regulatory framework rewards preparation, precision, and local expertise. The brands that succeed are those that treat compliance not as a hurdle but as a foundation for long-term market presence.

Whether you are bringing supplements, cosmetics, health tech devices, or functional foods to Japan, the regulatory path is navigable with the right guidance. The cost of doing it wrong -- in time, money, and reputation -- far exceeds the cost of doing it right the first time.

We specialize in bringing international wellness brands to the Japanese market. Our regulatory team handles classification, documentation, labeling, and approval management so you can focus on building your brand. Schedule a free consultation

Japan Regulatory Guide for Wellness Products: What You Need to Know